3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Glioblastoma
77
Prostatic Neoplasms
56
Carcinoma, Non-Small-Cell Lung
49
Breast Neoplasms
49
Esophageal Neoplasms
47
Rectal Neoplasms
41
Lung Neoplasms
39
Squamous Cell Carcinoma of Head and Neck
32
Gliosarcoma
31
Head and Neck Neoplasms
30
Pancreatic Neoplasms
29
Brain Neoplasms
29
Uterine Cervical Neoplasms
27
Neoplasm Metastasis
23
Glioma
23
Neoplasms
22
Oropharyngeal Neoplasms
20
Sarcoma
19
Esophageal Squamous Cell Carcinoma
19
Melanoma
18
Astrocytoma
17
Adenocarcinoma Of Esophagus
15
Stomach Neoplasms
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Carcinoma, Squamous Cell
12
Urinary Bladder Neoplasms
11
Lymphoma, Follicular
11
Central Nervous System Neoplasms
11
Carcinoma
11
Burkitt Lymphoma
10
Interventions
Carboplatin
7
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Epirubicin
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Observation
2
Monatide (IMS 3015)
2
Metformin
2
Leucovorin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pathologic Complete Response
×
Radiation
×
Clear all
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled